In a report released today, Lawrence Keusch from Raymond James maintained a Buy rating on Baxter International (BAX). The company’s shares closed last Thursday at $77.18.
According to TipRanks.com, Keusch is a 4-star analyst with an average return of 9.1% and a 71.1% success rate. Keusch covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Intuitive Surgical, and Becton Dickinson.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baxter International with a $90.38 average price target, representing a 17.9% upside. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $100.00 price target.
See today’s analyst top recommended stocks >>
Based on Baxter International’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.97 billion and net profit of $356 million. In comparison, last year the company earned revenue of $2.85 billion and had a net profit of $369 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Baxter International, Inc. provides portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies; premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems; and pharmacy automation, software and services. It operates through the following segment: Americas, Europe, Middle East & Africa and Asia-Pacific. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.
